Company intelligence / Profile preview

Beijing Immupeutics Medicine Technology Limited

Beijing, Beijing Municipality ("Beijing Shi"), Chinaimmupeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company’s lead program IPM001—an adoptive immune cell injection sensitized with multiple TAAs/TSAs—has entered Phase I clinical trials to evaluate safety, tolerability, pharmacodynamics, and preliminary efficacy in progressive or recurrent hepatocellular carcinoma. Early results are focused on safety/tolerability; efficacy data not yet published. Additional exploratory studies are ongoing or planned for high-risk post-surgical patients.

Therapeutic areas: Oncology
Modalities: mRNA vaccinesTCR bispecificsin vivo TCR-T therapiesAutoimmune cell therapy (adoptive immune cell therapy)
Industry: Biotech

Partnerships

Peking Union Medical College Hospital – clinical trial collaboration/sponsorship partner for HCC study NCT05536427.Shanghai Huashan Hospital – sponsor/collaborator on early phase HCC recurrence prevention study NCT05105815.

Beyond the preview

Go deeper on Beijing Immupeutics Medicine Technology Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Immupeutics Medicine Technology Limited.

Explore the full profile